3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
56
Breast Neoplasms
49
Ovarian Neoplasms
31
Triple Negative Breast Neoplasms
27
Endometrial Neoplasms
25
Lung Neoplasms
24
Fallopian Tube Neoplasms
22
Neoplasm Metastasis
21
Squamous Cell Carcinoma of Head and Neck
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
18
Neoplasms
14
Esophageal Squamous Cell Carcinoma
12
Esophageal Neoplasms
12
Carcinoma, Ovarian Epithelial
9
Stomach Neoplasms
8
Head and Neck Neoplasms
8
Colorectal Neoplasms
8
Carcinoma
7
Adenocarcinoma Of Esophagus
7
Peritoneal Neoplasms
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Melanoma
5
Oropharyngeal Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Transitional Cell
4
Small Cell Lung Carcinoma
3
Recurrence
3
Pancreatic Neoplasms
3
Mouth Neoplasms
3
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Paclitaxel
×
90 days
×
Clear all
No trials found.